Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess
efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic
Hyperplasia (BPH) , followed by a 12-month open-label treatment phase